Market Overview:
The global monoclonal antibody therapy market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer and autoimmune diseases, rising demand for monoclonal antibody therapies, and technological advancements in the field of monoclonal antibody therapy. Based on type, the global monoclonal antibody therapy market can be segmented into human monoclonal antibodies, humanized monoclonal antibodies, chimeric monoclonal antibodies, and murine monoclonal antibodies.
Product Definition:
Monoclonal antibody therapy is a form of cancer treatment that uses antibodies made in a lab to attach to and kill cancer cells. Monoclonal antibody therapy is important because it can specifically target cancer cells, which may help reduce side effects.
Human Monoclonal Antibody:
Human monoclonal antibody, also called humanized or fully human antibody is an antibody with unique binding specificity for a particular antigen. They are produced by immunizing humans with the aid of DNA fragments derived from the genes of antibodies found in livestock and other species. The most commonly used DNA fragment to produce human antibodies is the heavy (H) chain of a mouse anti-human immunoglobulin molecule.
Humanized Monoclonal Antibody:
Humanized monoclonal antibody is a type of monoclonal antibody (mAb) that binds to an epitope on the antigen (body tissue or fluid-based disease marker) with high affinity and specificity. The binding of humanized mAb usually enhances the immune response by promoting antigen presentation in the mAbs' immune recognition mechanism.
Application Insights:
The application segment is segregated into cancer, autoimmune diseases, and others. Cancer dominated the overall market in terms of revenue share in 2017. Monoclonal antibodies are used for treatment of various cancers such as lung, breast, colorectal, prostate and lymphoid malignancies. The rising prevalence of cancer across the globe is anticipated to boost the growth during the forecast period.
Moreover, increasing research & development activities by key players coupled with growing approval for new drug candidates are further expected to propel market growth over the forecast period. For instance; on January 29th 2018 FK-T826 monoclonal antibody therapy was approved by U.S FDA for treatment of non-small cell lung carcinoma which is a type of adenocarcinoma that invades surrounding tissues (surgery) and spreads to other parts). This approval was based on data from clinical trials which showed positive outcomes in patients suffering from this type double negative tumor disease (TDL).
Regional Analysis:
North America dominated the global monoclonal antibody therapy market in 2017, with a revenue share of over 40%. The growth is attributed to the presence of key players such as AbbVie Inc.; F. Hoffman La-Roche Ltd.; and Genentech, Inc., which are engaged in drug development activities. Moreover, these companies are also focusing on increasing their R&D capabilities by collaborating with universities and other organizations to develop novel therapies for patients around the world.
Asia Pacific region is expected to witness lucrative growth during the forecast period owing to rising investments by major players for expanding their operations in this region coupled with growing awareness about new treatment options among patients suffering from chronic diseases such as cancer & autoimmune disorders. Furthermore, increasing healthcare expenditure levels by governments across countries like China & India will further boost regional demand during the forecast period.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the monoclonal antibody therapy market. According to a study by the World Health Organization (WHO), an estimated 14 million new cases of cancer were diagnosed in 2012, and this number is expected to increase to 21 million by 2030. This will create a large pool of patients who will require treatment with monoclonal antibodies, thereby driving the growth of this market.
- Technological advancements: The development and commercialization of novel technologies such as chimeric antigen receptor T-cell therapy (CAR-T) are expected to drive the growth of the monoclonal antibody therapy market in coming years. These technologies have shown promising results in clinical trials and are likely to be approved for use in mainstream medicine in near future, thereby expanding the patient base for monoclonal antibodies therapies.
- Growing demand for personalized medicines: A growing trend towards personalized medicines is another key factor that is expected to drive demand for monoclonal antibody therapies in coming years. With advances in genomic sequencing technology, it has become possible to identify specific genetic mutations that are associated with particular diseases such as cancer. This information can be used to develop targeted therapies that are more effective and cause fewer side effects than traditional chemotherapy regimens. Monoclonal antibodies represent an important class of targeted therapeutics and their popularity is likely to grow further as personalized medicine becomes more prevalent worldwide .
Scope Of The Report
Report Attributes
Report Details
Report Title
Monoclonal Antibody Therapy Market Research Report
By Type
Human Monoclonal Antibody, Humanized Monoclonal Antibody, Chimeric Monoclonal Antibody, Murine Monoclonal Antibody
By Application
Cancer, Autoimmune Diseases, Others
By Companies
Abbvie, Amgen, Glaxosmithkline, Merck, Novartis, Roche, Johson & Johson, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Monoclonal Antibody Therapy Market Report Segments:
The global Monoclonal Antibody Therapy market is segmented on the basis of:
Types
Human Monoclonal Antibody, Humanized Monoclonal Antibody, Chimeric Monoclonal Antibody, Murine Monoclonal Antibody
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Autoimmune Diseases, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbvie
- Amgen
- Glaxosmithkline
- Merck
- Novartis
- Roche
- Johson & Johson
- Novartis
Highlights of The Monoclonal Antibody Therapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Human Monoclonal Antibody
- Humanized Monoclonal Antibody
- Chimeric Monoclonal Antibody
- Murine Monoclonal Antibody
- By Application:
- Cancer
- Autoimmune Diseases
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Monoclonal Antibody Therapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Monoclonal antibody therapy is a type of cancer treatment that uses antibodies to attack and destroy cancer cells. Monoclonal antibodies are made from one type of immune cell, called a monocyte, which is isolated from the blood or bone marrow of an animal. These antibodies can be directed against specific proteins on the surface of cancer cells. When these antibodies attach to the cancer cells, they can start to damage them and eventually kill them.
Some of the major companies in the monoclonal antibody therapy market are Abbvie, Amgen, Glaxosmithkline, Merck, Novartis, Roche, Johson & Johson, Novartis.
The monoclonal antibody therapy market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Monoclonal Antibody Therapy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Monoclonal Antibody Therapy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Monoclonal Antibody Therapy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Monoclonal Antibody Therapy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Monoclonal Antibody Therapy Market Size & Forecast, 2018-2028
4.5.1 Monoclonal Antibody Therapy Market Size and Y-o-Y Growth
4.5.2 Monoclonal Antibody Therapy Market Absolute $ Opportunity
Chapter 5 Global Monoclonal Antibody Therapy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Monoclonal Antibody Therapy Market Size Forecast by Type
5.2.1 Human Monoclonal Antibody
5.2.2 Humanized Monoclonal Antibody
5.2.3 Chimeric Monoclonal Antibody
5.2.4 Murine Monoclonal Antibody
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Monoclonal Antibody Therapy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Monoclonal Antibody Therapy Market Size Forecast by Applications
6.2.1 Cancer
6.2.2 Autoimmune Diseases
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Monoclonal Antibody Therapy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Monoclonal Antibody Therapy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Monoclonal Antibody Therapy Analysis and Forecast
9.1 Introduction
9.2 North America Monoclonal Antibody Therapy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Monoclonal Antibody Therapy Market Size Forecast by Type
9.6.1 Human Monoclonal Antibody
9.6.2 Humanized Monoclonal Antibody
9.6.3 Chimeric Monoclonal Antibody
9.6.4 Murine Monoclonal Antibody
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Monoclonal Antibody Therapy Market Size Forecast by Applications
9.10.1 Cancer
9.10.2 Autoimmune Diseases
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Monoclonal Antibody Therapy Analysis and Forecast
10.1 Introduction
10.2 Europe Monoclonal Antibody Therapy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Monoclonal Antibody Therapy Market Size Forecast by Type
10.6.1 Human Monoclonal Antibody
10.6.2 Humanized Monoclonal Antibody
10.6.3 Chimeric Monoclonal Antibody
10.6.4 Murine Monoclonal Antibody
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Monoclonal Antibody Therapy Market Size Forecast by Applications
10.10.1 Cancer
10.10.2 Autoimmune Diseases
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Monoclonal Antibody Therapy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Monoclonal Antibody Therapy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Monoclonal Antibody Therapy Market Size Forecast by Type
11.6.1 Human Monoclonal Antibody
11.6.2 Humanized Monoclonal Antibody
11.6.3 Chimeric Monoclonal Antibody
11.6.4 Murine Monoclonal Antibody
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Monoclonal Antibody Therapy Market Size Forecast by Applications
11.10.1 Cancer
11.10.2 Autoimmune Diseases
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Monoclonal Antibody Therapy Analysis and Forecast
12.1 Introduction
12.2 Latin America Monoclonal Antibody Therapy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Monoclonal Antibody Therapy Market Size Forecast by Type
12.6.1 Human Monoclonal Antibody
12.6.2 Humanized Monoclonal Antibody
12.6.3 Chimeric Monoclonal Antibody
12.6.4 Murine Monoclonal Antibody
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Monoclonal Antibody Therapy Market Size Forecast by Applications
12.10.1 Cancer
12.10.2 Autoimmune Diseases
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Monoclonal Antibody Therapy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Monoclonal Antibody Therapy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Monoclonal Antibody Therapy Market Size Forecast by Type
13.6.1 Human Monoclonal Antibody
13.6.2 Humanized Monoclonal Antibody
13.6.3 Chimeric Monoclonal Antibody
13.6.4 Murine Monoclonal Antibody
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Monoclonal Antibody Therapy Market Size Forecast by Applications
13.10.1 Cancer
13.10.2 Autoimmune Diseases
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Monoclonal Antibody Therapy Market: Competitive Dashboard
14.2 Global Monoclonal Antibody Therapy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbvie
14.3.2 Amgen
14.3.3 Glaxosmithkline
14.3.4 Merck
14.3.5 Novartis
14.3.6 Roche
14.3.7 Johson & Johson
14.3.8 Novartis
